How many investments has OrbiMed made?

OrbiMed has 205 tracked investments, 2 of which have exited via acquisition or IPO, including 12 dated in the last 24 months.

What stage does OrbiMed invest at?

OrbiMed invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is OrbiMed's typical check size?

OrbiMed typically writes checks of $1M – $75M.

What sectors does OrbiMed focus on?

OrbiMed focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is OrbiMed located?

OrbiMed is headquartered in New York, US.

Does OrbiMed lead rounds?

Yes, OrbiMed leads investment rounds.

Who does OrbiMed co-invest with?

OrbiMed most often shares deals with RA Capital, Foresite Capital, Frazier Life Sciences, among 218 tracked co-investors.

OrbiMed

Venture capitaloperating company · company profile

New York · Pre-Seed–Late Stage · 117 people tracked

Also known as ORBIMED ADVISORS LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

OrbiMed invests globally across the healthcare industry, backing companies from early-stage private ventures to large multinational corporations. Its focus spans biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, with the aim of supporting innovations that help people live healthier, longer, and more productive lives. The firm brings tailored financing solutions alongside global team resources drawn from scientific, medical, and investment professionals to help build world-class healthcare companies.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Asia-Pacific Europe Global New York North America

Source: firm website, verified Aug 25, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $75M

New York, NY, US

Leads rounds

Leads

Instruments

Equity · Debt

Founded

1999

Last 12 months

13 investments

AUM

$20.6B

Tracked investments

284

Team · 117 people

from the firm's website & public directories

David Bonita· General Partner· New York, New Yorkin

David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.

David Wang· Partner and Senior Managing Director· Greater Chinain

David Wang is a Partner and Senior Managing Director on OrbiMed's Asia team, focused on Greater China, which he joined in 2011. He previously led healthcare investments in China as a Managing Director at WI Harper Group and served as Head of Business Development at Siemens Medical Solutions, overseeing molecular diagnostics and diagnostic imaging strategy. He co-founded personalized medicine company First Genetic Trust as EVP, chaired The SNP Consortium Management Committee while at Bristol-Myers Squibb, and holds an M.D. from Peking University Medical School and a doctorate in Developmental Biology from Caltech.

Dina Chaya· Partner· Londonin

Dina Chaya is a Partner on the Private Equity team at OrbiMed, with healthcare investment experience in Europe and the US since 2001 across private equity and venture capital. Her prior roles include positions at Omega Funds, NeoMed Management, 3i Group, and Index Ventures, and her portfolio includes investments in companies acquired by Merck, AstraZeneca, Alexion Pharmaceuticals, and Jazz Pharmaceuticals. Chaya holds a CFA charter and a Ph.D. in Molecular and Cellular Biology from Paris VI University, with postdoctoral research experience at Brown University and Fox Chase Cancer Centre.

Evan Caplan· Partner· San Francisco Bay Areain

Partner at OrbiMed holding an M.D.

Geoffrey Hsu· General Partner· New York, New Yorkin

Geoffrey C. Hsu combines Harvard Medical School training and healthcare investment-banking experience with long-tenured public-equity portfolio management since 2005 and a London-listed biotech trust role, giving him cross-border market insight.

Mona Ashiya· General Partner· New York, New Yorkin

Mona Ashiya is a General Partner at OrbiMed, which she joined in 2010. She previously worked on J.P. Morgan's biotechnology equity research team and held positions at the Global Alliance for TB Drug Development and Harvard Business School. She holds a B.A. from the University of California, Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and completed a post-doctoral fellowship at the Dana Farber Cancer Institute.

Peter Thompson· General Partner· Bellevue, Washingtonin

Peter Thompson is a General Partner at OrbiMed, which he joined in 2010, with over 25 years of industry experience. He previously held executive roles at Becton-Dickinson and Chiron, co-founded and served as CEO of Trubion Pharmaceuticals, co-founded several OrbiMed portfolio companies, and worked at the National Cancer Institute after internal medicine training at Yale. He holds a bachelor's degree in Molecular Biology and Mathematics and a medical degree from Brown University, and is a board-certified internist and oncologist.

Steven D. Wang· Partner· Huangpu District, Shanghai, Chinain

Sunny Sharma· Partnerin

Partner at OrbiMed holding an M.D.

Sven Borho· Managing Partner· New York, New York

Sven H. Borho, a founding partner, leads public equities and portfolio management for listed healthcare strategies, uniquely combining specialist biomedical expertise with a science-first approach prioritizing biology and clinical science.

Tal Zaks· Partner· Newton, Massachusetts, United Statesin

Partner at OrbiMed holding both M.D. and Ph.D. degrees.

Topher Orr· Partner· New York, New Yorkin

Trevor Polischuk· Partner· New York, New Yorkin

Trevor Polischuk joined OrbiMed in 2003 as the Global Pharmaceutical Analyst covering Japan, and became a Partner in 2011, later serving as co-Portfolio Manager of the Worldwide Healthcare Trust. He previously worked as a Senior Research Analyst covering the U.S. pharmaceutical industry at Lehman Brothers and began his career on the Pharmaceutical Global Marketing Planning team at Warner-Lambert. He holds a B.S. in Biology and a Ph.D. in Neuropharmacology and Gross Human Anatomy from Queen's University, as well as an M.B.A. from Queen's M.B.A. for Science & Technology program.

W. Carter Neild· Managing Partner· New York, New Yorkin

Carter Neild spearheads expansion into healthcare royalties and Asia-focused private investments, combining a hybrid background in alternatives and bank-affiliated asset management (UBS, First Chicago) with deep University of Chicago ties.

Iris Wang· Partner· Hong Kongin

Rishi Gupta· Partner· San Francisco, Californiain

William Sawyer· Partner· New York, New Yorkin

Jonathan Mandelbaum· Principal· New York, New Yorkin 𝕏

Jonathan Mandelbaum is a Principal at OrbiMed, a healthcare venture capital firm. He previously worked as a drug discovery scientist and focuses on biotech company formation and medicine development.

Kip Kitur· Principal· New York, New Yorkin

Kip Kitur is a Principal on the Private Equity team at OrbiMed, focusing on healthcare investments. Previously, he worked as a Consultant in The Boston Consulting Group's Healthcare practice in New York and co-founded Sarora Dairies LLC/Ltd, which processes and distributes dairy products in Kenya. He holds a Ph.D. in Pharmacology from Columbia University and a B.A. in Chemistry from Harvard College.

Vivek Sivathanu· Principal· New York, New Yorkin

Sivathanu is a Principal at OrbiMed Advisors, where he invests in biotech, medtech, and diagnostics companies across their development lifecycle. He previously worked as a biotechnology equity research analyst at Evercore ISI and as a management consultant at Simon-Kucher, focusing on drug pricing and commercial strategy in the biopharma and medtech sectors. He holds a Ph.D. in Biomedical Engineering and Technology Commercialization from MIT, with research focused on muscle strength enhancement and personalized medicine approaches in cancer therapy.

Dimitri Krainc· Venture Partner· Chicago, Illinoisin

Iain Dukes· Venture Partner· Philadelphia, Pennsylvaniain

Iain Dukes is a Venture Partner at Orbimed and CEO of Viriom Inc, serving on the executive teams or boards of nine companies across the USA, France, and the UK. His career includes roles as Senior Vice President of Business Development & Licensing at Merck, where he managed licensing deals for Merck Research Laboratories, as well as Vice President of External Research and Development at Amgen, President and CEO of Essentialis Therapeutics, and Vice President of Scientific and Technology Licensing at GlaxoSmithKline. He holds a BSc in Pharmacology from the University of Bath, an MSc in Cardiovascular Studies from the University of Leeds, a DPhil in Physiology and Pharmacology from the University of Oxford, and an MA in Jurisprudence and Law from the University of Oxford.

Kevin Koch· Venture Partner· Boulder, Coloradoin

Kevin Koch is President and CEO of Edgewise Therapeutics, a public biotechnology company he founded. Over 12 years, the company developed 21 investigational new drugs across multiple therapeutic areas. Koch has experience in corporate strategy, investor relations, and business development within vertically integrated, research-driven organizations.

Klaus Veitinger· Venture Partner· New York, New Yorkin

Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.

Robert Glassman· Venture Partner· New Jersey

Sevgi Gurkan· Venture Partner· San Francisco Bay Areain 𝕏

Sevgi Gurkan joined OrbiMed in 2018 as a Venture Partner. She was previously a founding member of Merck Research Laboratories' South San Francisco Discovery site and a Director in Early Drug Development at MRL. Earlier in her career she was an Associate Professor at Rutgers, Director of the Pediatric Kidney Transplant Program at RWJ University Hospital, and a pediatric nephrologist; she holds a medical degree from Hacettepe University and a Master of Science in Clinical Research from Mount Sinai School of Medicine.

Alexander M. Cooper in

Andrew P. Kanarek, CFA, CIPM in

Ankesh Bhansali in

Arun Sadhanandham in

Bob Smith· Venture Partnerin

Bob Smith joined OrbiMed in 2024 as a Venture Partner, bringing over thirty years of experience across alliance management, business development, commercial, M&A, and R&D roles. He retired from Pfizer in January 2024, where he led the company's global gene therapy business, its R&D business development activities, and strategic transactions team; he originally joined Pfizer in 2009 through its acquisition of Wyeth, where he led the global M&A group. He holds a B.S. in Neuroscience and an M.B.A. in Finance and Corporate Accounting from the University of Rochester.

Brian Glowatz in

C. Scotland Stevens· General Partner and Co-Head of Public Equity· New York, New Yorkin

Scot Stevens is a General Partner and Co-Head of Public Equity at OrbiMed, which he joined in 2005, where he leads trading activities across the firm's business units, geographies, and investment products. Before OrbiMed, he worked in Global Banking & Markets at Goldman, Sachs & Co., trading equity products for healthcare-focused hedge fund clients. He holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.S. in Business Administration with a minor in Chemistry from the University of North Carolina at Chapel Hill.

Carl Gordon· Managing Partner· New York City Metropolitan Areain

Carl Gordon, an MIT Ph.D. and CFA with early hands‑on ImClone experience, is a founding GP and Co‑Head of global private equity repeatedly named to Forbes' Midas List and media‑shy.

Dimitri Krainc, M.D., Ph.D.

Dimitrios Weedon in

Dina Chaya, Ph.D., CFA

Diyong Xu· Principal· New York, New Yorkin

Diyong Xu is a Partner at OrbiMed with a career progression spanning analyst, associate, vice president, and principal roles at the firm. His investment experience covers biotechnology, biopharmaceuticals, medical devices, and diagnostics across venture capital, private equity, and investment banking contexts.

Donnie McGrath, M.D., M.P.H.

Doug Coon in

Elizabeth Krane in

Emily Kalenik in

Erez Chimovits· Partnerin

Evan Caplan, M.D.in

Girish Bakhru, M.D., CFA

Guiyu Zhao, Ph.D.

Henry Yang

Howell Ma in

Iain D. Dukes, D.Phil.

Jamie Christensen, Ph.D.

Ji Wang· Chinain

Jim Sullivan, Ph.D.· Venture Partner· Greater Chicago Areain

Jim Sullivan joined OrbiMed as a Venture Partner in 2019 and serves as CEO of portfolio company Vanqua Bio, which develops therapeutics for neurological conditions such as Parkinson's disease. He previously was Vice President of Research at AbbVie, overseeing research across oncology, immunology, neurology, hepatitis C, and cystic fibrosis, and has advanced more than 100 compounds into clinical development. He holds a bachelor's degree and Ph.D. in biochemistry from Trinity College Dublin, completed postdoctoral research in neurobiology at Northwestern University, and is an adjunct faculty member there.

Jonathan Mandelbaum, Ph.D.

Joseph N. Kleeman in

Joshua Golomb· Partner· New York, New York, United Statesin

Joshua Golomb is a partner at OrbiMed Advisors, where he focuses on investments in therapeutics. His expertise spans global pharmaceuticals, specialty pharmaceuticals, and biotech.

Klaus Veitinger, M.D., Ph.D.

Lauren Ralph

Madeline Huber· New York, New York, United Statesin

Manjot Bhuller in

Mark R. Jelley· Partner· New York, New Yorkin

Mark Rolfe, Ph.D.

Matt Xie, M.D

Matthew Rizzo· Partner· New York, New York

Matthew Rizzo heads a royalty and credit team, directed over $6 billion in structured credit and royalty deals, and brings 30 years of healthcare experience including pharma licensing and acquisitions.

Michael Eggenberg· Partner· United Statesin

Mona Ashiya, Ph.D.

Peter Thompson, M.D.in

Priya Malebennur

Ran Geng in

Roy Amariglio, Ph.D.· United Statesin

Steven D. Wang, Ph.D., CFA

Sumona Chakraborty in

Sunny Sharma, M.D.in

Sven H. Borho, CFA

Tal Zaks, M.D., Ph.D.

Tara Garber in

Trey Block

Valerie Odegard, Ph.D.

Vicky Qu

Vivek Sivathanu, Ph.D.in

Alexandria Huynh· Analyst· New York, New Yorkin

Anat Nursella· Venture Partner· Israelin

Brendan Weber· Principal· Hoboken, New Jerseyin

Charles Steinman· Analyst· New York, New Yorkin

Jessica Zhang· Senior Associate· Boston, Massachusetts

Lars Enstrom· Managing Director· New York, New Yorkin

Natasha Shervani· Senior Associate· New York, New Yorkin

Nate Yee· Vice President· New York, New Yorkin

William Price· Managing Director· New York, New Yorkin

Founder mafia

The OrbiMed mafia →

7 people who came through OrbiMed went on to found or lead other companies.

Peter ThompsonGeneral PartnerFounded Cleave Biosciences +4 Iain DukesVenture PartnerFounded Viriom +1 Kevin KochVenture PartnerFounded Arraybiopharma +1 Tadd WesselPartnerFounded Petrichor Steven YeciesConsultantFounded Javelin Oncology Sevgi GurkanVenture PartnerFounded Perfuse Therapeutics Jim Sullivan, Ph.D.Venture PartnerFounded Vanquabio

What they invest in

from 239 of 284 portfolio companies

Biotech ×184Healthtech ×143Medical Devices ×72Digital Health ×31AI & Machine Learning ×29Deep Tech ×21Hardware ×12Consumer ×8

HQs:United States×130China×10India×7Switzerland×2United Kingdom×2Australia×1

Who they back

founder profiles across 58 portfolio companies

59%

solo founders

34 of 58 mapped founding teams

26%

repeat founders

of 23 founders with career history

~4 yrs

old at investment

median across 19 dated deals

Founding team size:solo founder×342 founders×173 founders×44+ founders×3

Where their founders studiedfrom 17 founders with education data

IE Business School ×2Tel Aviv University ×2

Where their founders worked beforefrom 23 founders with career history

Aisling Capital ×2Amgen ×2Stanford University ×2

Accelerator rootsportfolio companies that came through a program

Y Combinator ×2

13 founders hold a PhD · 4 hold an MBA (of 22 with degree data)

Investments · 284 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 19 2024 · 6 2023 · 4 2022 · 2 2021 · 9 2020 · 5 2019 · 7 2018 · 4 2017 · 2 2016 · 8 2015 · 982 dated

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTB✓ verified

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)Michael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)Lee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)

Co-investorsAtlas Venture CU Healthcare Innovation Fund OUP (Osage University Partners)Sanofi Ventures Agent Capital

Scribe Therapeuticsscribetx.com in 𝕏NASDAQ: SCTXMar 2021✓ verified

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)

BoardVijay Pande(Director)in

Co-investorsAndreessen Horowitz Avoro Capital Advisors Menlo Ventures RA Capital Avoro Ventures

Aadi Bioscienceaadibio.com inNASDAQ: WHWKMar 2017SEC filingmedium confidence

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017

Co-investors3B Future Health Fund Ally Bridge Group Decheng Capital Vivo Capital Avoro Ventures

Adicet Bioadicetbio.comNASDAQ: ACETAug 2015

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardFlorent Gros(Director)Erez Chimovits(Director)in

Board seatJonathan SilversteinCarl Gordon· per SEC Form D

Co-investorsForesite Capital Pontifax Venture Capital Quan Capital aMoon Novartis Venture Fund

Arvinas Holding Co. LLCarvinas.com in 𝕏NASDAQ: ARVNOct 2015SEC filingmedium confidence

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)

BoardLiam Ratcliffe(Director)Tim Shannon(Director)inKush Parmar(Director)

Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018

Co-investors5AM Ventures Access Biotechnology Canaan Partners Connecticut Innovations Nextech Invest RA Capital +1 more

Calcimedica inNASDAQ: CALCJul 2019SEC filingmedium confidence

BiotechLa Jolla, US

Eric W. Roberts(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Sudarshan Hebbar(Executive Officer)Michael J. Dunn(Executive Officer)

Board seatChau Khuong· per SEC Form D · $80M raise · filed Aug 2019

Co-investorsSanderling Ventures Clarus

Compass Therapeuticscompasstherapeutics.com in 𝕏NASDAQ: CMPXJun 2020

Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)Errik Anderson(Executive Officer, Director)Steve Tregay(Director)

Board seatStephen SquintoCarl Gordon· per SEC Form D

Co-investorsBioBrit F-Prime Capital Foresite Capital venBio Partners Vivo Capital

ImaraNASDAQ: ELVNMar 2019

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)

Board seatDavid Bonita· per SEC Form D

Co-investorsBay City Capital New Enterprise Associates (NEA)RA Capital Arix Bioscience

Keros TherapeuticsNASDAQ: KROSMar 2020SEC filingmedium confidence

BiotechLexington, US

Jasbir S. Seehra(Executive Officer, Director)

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)

Board seatCarl Gordon· per SEC Form D · $56M raise · filed Mar 2020

Co-investorsArkin Capital Foresite Capital

Mirna TherapeuticsOTC: SYBXJun 2019SEC filingmedium confidence

BiotechAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)Paul Lammers(Executive Officer, Director)Jon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019

Co-investorsPfizer Venture Investments

NextCurenextcure.comNASDAQ: NXTCDec 2015SEC filingmedium confidence

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)

Board seatChau Khuong· per SEC Form D · $93.4M raise · filed Nov 2018

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Pfizer Venture Investments Quan Capital +2 more

Prelude Therapeuticspreludetx.com in 𝕏NASDAQ: PRLDJun 2016

Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors.

BiotechHealthtechNewark, US

Krishna Vaddi(Executive Officer, Director)

BoardPaul Friedman(Director of Issuer)

Board seatDavid Bonita· per SEC Form D

Co-investorsThe Innovation Space

SI-BONENASDAQ: SIBNJun 2016SEC filingmedium confidence

San Jose, US

Mark Reiley(Director)Jeffrey Dunn(Executive Officer, Director)Mark A. Reiley(Director)Jeffrey W. Dunn(Executive Officer, Director)Laura Francis(Executive Officer)Robert E. Johnson(Executive Officer)

Board seatDavid Bonita· per SEC Form D · $21M raise · filed Jun 2016

Co-investorsArboretum Ventures

Spruce Biosciencessprucebiosciences.com in 𝕏NASDAQ: SPRBFeb 2020SEC filingmedium confidence

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)

BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in

Board seatDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023

Co-investorsAisling Capital HealthCap RiverVest Venture Partners Abingworth Norwest Venture Partners

Synlogicsynlogictx.com in 𝕏OTC: SYBXMay 2017SEC filingmedium confidence

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)

Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017

Co-investorsAtlas Venture New Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Sofinnova Ventures Solasta Ventures

Adaptive Biotechnologiesadaptivebiotech.com in 𝕏NASDAQ: ADPT

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Executive Officer, Director)Harlan Robins(Executive Officer)inKathleen Determann(Executive Officer)Dean Schorno(Executive Officer)Chris Carlson(Executive Officer)

BoardArnold Levine(Director)

Co-investorsDecheng Capital FMG Capital Foresite Capital Khosla Ventures

Alumisalumis.com in 𝕏NASDAQ: ALMS

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)

Co-investorsForesite Capital Nextech Invest Samsara BioCapital SR One Capital Management venBio Partners Westlake Village BioPartners +1 more

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos, Ph.d.(President and Treasurer)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)

Co-investorsAdvent Life Sciences Chiesi Ventures Droia Ventures Foresite Capital Jazzya Investments Medicxi +4 more

Avita Medicalavitamedical.com in 𝕏NASDAQ: RCELNov 2019

AVITA Medical develops therapeutic acute wound care technologies, including the FDA-approved RECELL System that uses a patient's own skin to create a Spray-On Skin cell suspension for treating thermal burn wounds and full-thickness skin defects.

BiotechHealthtechMedical DevicesMelbourne, US

Dale A Sander(Executive Officer)

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)Dov Goldstein(Executive Officer)

BoardPatrick Enright(Director)in

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures IA Seed Ventures Longitude Capital Pear VC +2 more

BiomXbiomx.com in 𝕏NYSE: PHGE

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.

AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardware

Jonathan Solomon(Chief Executive Officer)Merav Bassan(Chief Development Officer)Marina Wolfson(Chief Financial Officer)Jesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)

Co-investorsAMR Action Fund Baruch Future Ventures NSG Ventures 8VC

Caris Life Sciencescarislifesciences.com in 𝕏NASDAQ: CAI

Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.

AI & Machine LearningBiotechHealthtech

David Dean Halbert(Chairman, Founder and CEO)

Co-investorsCoatue Management Silver Lake Partners Sixth Street

Cullinan Therapeuticscullinantherapeutics.com in 𝕏NASDAQ: CGEM

Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.

BiotechHealthtech

Co-investorsForesite Capital Nextech Invest Biotechnology Value Fund

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Foresite Capital Frazier Life Sciences

Emergent Biosolutionsemergentbiosolutions.com in 𝕏NYSE: EBSOct 2018

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

Fuad El-Hibri(Director, Executive Officer)Robert G Kramer(Executive Officer)Katherine Strei(Executive Officer)Adam R Havey(Executive Officer)Daniel J Abdun-Nabi(Executive Officer, Director)Zsolt Harsanyi(Director)

Co-investorsAdvent Life Sciences

Enliven Therapeuticsenliventherapeutics.com inNASDAQ: ELVN

Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).

BiotechHealthtechBoulder, US

Co-investors5AM Ventures Pfizer Venture Investments Roche Venture Fund ARCH Venture Partners

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will LewisinGeoffrey Allanin

Co-investorsBessemer Venture Partners F-Prime Capital Foresite Capital Prospect Venture Partners NVIDIA

InspireMDinspiremd.comNASDAQ: NSPR

BiotechHealthtechMiami, US

Patrick Verta(Executive Officer)Pete Ligotti(Executive Officer)Mike Lawless(Chief Financial Officer)Shane Gleason(Executive Officer)Marvin Slosman(President and Chief Executive Officer)Andrea Tommasoli(Chief Operating Officer)

NeuroPaceneuropace.com in 𝕏NASDAQ: NPCEAug 2020

NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.

Digital HealthHardwareHealthtechMedical DevicesMountain View, US

Rebecca Kuhn(Executive Officer)Frank Fischer(Executive Officer, Director)Vince Burgess(Director)Renee Ryan(Director)Ray Larkin(Director)Greg Garfield(Director)

Co-investorsAccelmed Partners New Enterprise Associates (NEA)

Oncology InstituteNASDAQ: TOI

HealthtechCerritos, US

Robert Carter(Executive Officer)Jeremy Castle(Executive Officer)Daniel Virnich(Executive Officer, Director)Yale Podnos(Executive Officer)Brad Hively(Director)Mihir Shah(Executive Officer)

Shattuck Labsshattucklabs.com inNASDAQ: STTK

Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases.

BiotechAustin, US

Josiah Hornblower(President/CEO)

BoardWalter Loewenbaum(Director)

Co-investorsEcoR1 Capital Hatteras Venture Partners T. Rowe Price

SonendoOTC: SONX

HealthtechLaguna Hills, US

Bjarne Bergheim(Executive Officer, Director)John McGaugh(Executive Officer)John Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)

BoardOlav Bergheim(Director)Olav B. Bergheim(Director)

Co-investorsEssex Woodlands Healthcare Partners Fjord Ventures General Atlantic Meritech Capital Partners Welsh, Carson, Anderson & Stowe

TELA Bio in 𝕏NASDAQ: TELA

BiotechMalvern, US

Antony Koblish(Executive Officer, Director)Francis Conway(Executive Officer)Maarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)Vince Burgess(Director)

BoardKevin Rakin(Director)

Co-investorsCheckmate Capital Group LLC Essex Woodlands Healthcare Partners Signet Healthcare Partners 1315 Capital

Trawspharmatrawspharma.comNASDAQ: TRAW

Traws Pharma is a clinical-stage biopharmaceutical company developing oral small molecule antiviral therapies for respiratory viral diseases.

BiotechHealthtech

Upstream Bioupstreambio.com in 𝕏NASDAQ: UPB

Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.

BiotechHealthtech

Rand Sutherlandin

Co-investorsAccess Biotechnology Bain Capital Life Sciences Decheng Capital Samsara BioCapital TCG Crossover Venrock Healthcare Capital Partners

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)

Co-investorsBessemer Venture Partners Cardinal Partners Foresite Capital Lightstone Ventures Longwood Fund Oberland Capital

Aer Therapeuticsaertherapeutics.com in✓ verified

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.

BiotechHealthtechMedical DevicesRaleigh, US

THOMAS MATHERS(Executive Officer, Director)James Shaffer(Executive Officer, Director)Thomas Mathers(Executive Officer, Director)John Fahy(Director)in

BoardChristy Shaffer(Director)inRishi Gupta(Director)

Co-investorsHatteras Venture Partners Canaan Partners Pappas Capital

Aspen Neuroscienceaspenneuroscience.com in 𝕏✓ verified

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical Devices

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)

Co-investorsARCH Venture Partners Lifeforce Capital Domain Associates EDB Investments Section 32 Frazier Life Sciences +3 more

Brenigbrenigther.com in 𝕏✓ verified

Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery.

AI & Machine LearningBiotechHealthtech

Megan McGill(Chief Executive Officer)Iain Dukes(Chief Business Officer / Chairman of the Board)Nikolay Savchuk(Chief Operating Officer)Tien Dam(Chief Medical Officer)

Co-investorsNew Enterprise Associates (NEA)BGV Torrey Pines Investment

Congruencetxcongruencetx.com in✓ verified

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)

Co-investorsAlexandria DIMENSION BDC Thrive Venture Fund for Women Lumira Ventures

GentiBiogentibio.com in 𝕏✓ verified

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)Tom Wickham(Chief Scientific Officer)

Co-investorsNovartis Venture Fund JDRF T1D Fund RA Capital

i2020 Acceleratori2020accelerator.com in✓ verified

i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.

BiotechDeep TechHealthtech

Co-investorsTorrey Pines Investment BioGeneration Ventures

Latticemedtechlatticemedtech.com in✓ verified

Lattice MedTech operates a medical device distribution and manufacturing platform in India, serving global brands and Indian manufacturers across specialties such as cardiology, orthopedics, general surgery, critical care, and IVD.

HealthtechLogistics & Supply ChainMedical Devices

Oncusp Therapeuticsoncusptx.com in✓ verified

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)

Co-investorsCatalio Capital Management, LP F-Prime Capital Sofinnova Ventures Insight Partners NVIDIA

Sionnatxsionnatx.com in 𝕏✓ verified

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsAtlas Venture RA Capital

Siriusrnasiriusrna.com✓ verified

Sirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets.

BiotechHealthtech

Co-investorsDelos Capital Creacion Ventures

Variantyxvariantyx.com inFeb 2021✓ verified

Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.

AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US

Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in

Co-investors20/20 HealthCare Partners LLC Bosch Ventures New Era Capital Partners Peregrine Ventures Pitango Quark Venture Inc.+2 more

Acutus Medicalacutusmedical.comJun 2022

HealthtechCarlsbad, US

Christoph Scharf(Director)Randy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)Vince Burgess(Director)John Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Board seatDavid Bonita· per SEC Form D

Co-investorsAdvent Life Sciences Deerfield Management Company GE Ventures Index Ventures

Adelabioadelabio.com in 𝕏Apr 2026

Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.

BiotechDigital HealthHealthtechFoster City, US

Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)

Board seatDavid Bonita· per SEC Form D

Co-investorsDecheng Capital F-Prime Capital Deerfield Management Company Menlo Ventures

Aerpio Therapeuticsaerpio.comMar 2016SEC filingmedium confidence

BiotechCincinnati, US

Joseph H. Gardner(Executive Officer)Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)

Board seatChau Khuong· per SEC Form D · $9.2M raise · filed Apr 2016

Co-investorsCincyTech Sofinnova Ventures

Alpheus Medicalalpheusmedical.com inMay 2025

Clinical-stage company developing novel treatment for recurrent high-grade gliomas

HealthtechChanhassen, US

Jeremy Ling(Executive Officer)Steve Weiner(Executive Officer)Vijay Agarwal(Executive Officer, Director)William Davis(Executive Officer, Director)

BoardImran Eba(Executive Officer)in

Board seatKlaus Veitinger· per SEC Form D

Co-investorsSV Health Investors Action Potential Venture Capital Ltd.

Angiexangiex.com in 𝕏Jul 2025SEC filingmedium confidence

Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.

BiotechHealthtechMedical DevicesCambridge, US

Paul Jaminet(Executive Officer, Director)in

BoardErrik Anderson(Director)Jason Camm(Director)inJonathan Adams(Director)inFabian Hansen(Director)in

Board seatIain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025

Co-investorsGreen Meadow Ventures K5 Global

Audentes Therapeuticsastellasgenetherapies.com inAug 2015SEC filingmedium confidence

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)

BoardSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)

Board seatJonathan Silverstein· per SEC Form D · filed Sep 2015

Co-investorsAsset Management Company RA Capital venBio Partners Deerfield Management Company Venrock

Averna TherapeuticsApr 2024SEC filingmedium confidence

Creates gene therapies that integrate therapeutic genes into patients' genomes to treat genetic disorders.

HealthtechWatertown, US

Thomas Barnes(Chief Executive Officer/President)Richard Morris(Chief Financial Officer)

BoardRoy Amariglio(Director)Nick Olsen(Director)Michal Silverberg(Director)

Board seatStephen Squinto· per SEC Form D · $85M raise · filed Mar 2026

Co-investorsDeep Insight Novartis Venture Fund

Belenosbiobelenosbio.comJul 2024

Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU.

BiotechHealthtechNew York, US

Donnie McGrath(CEO & Co-Founder)Megan Dow(COO & Co-Founder)Tania Dimitrova(CFO & Co-Founder)Glenn Rosen(Chief Translational Officer & Co-Founder)StJohn Donnie McGrath(Executive Officer, Director)

BoardBo Chen(Director)

Board seatCarl Gordon· per SEC Form D

BELLUS HealthDec 2018SEC filingmedium confidence

BiotechLaval

Francois Desjardins(Vice President, Finance)Denis Garceau(Senior Vice President, Drug Development)Franklin Berger(Director)Roberto Bellini(President and Chief Executive Officer)Joseph Rus(Director)Youssef L. Bennani(Director)

Board seatChau Khuong· per SEC Form D · $24M raise · filed Jan 2019

Cerapedicscerapedics.com in 𝕏Feb 2015SEC filingmedium confidence

Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.

BiotechHealthtechMedical DevicesWestminster, US

Andrew J Tofe(Director)Britt Pearson(Executive Officer)Jeff Marx(Executive Officer)Glen Kashuba(Executive Officer, Director)Jerome Connor(Executive Officer)Andrew Handwerker(Executive Officer)

Board seatChau KhuongJonathan Silverstein· per SEC Form D · $4M raise · filed Feb 2015

Chemomabchemomab.com inMar 2021

Chemomab Therapeutics is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases.

BiotechTel Aviv

Adi Mor(Executive Officer, Director)Adi Mor George(Executive Officer, Director)Jill Quigley(Director)Sigal Fattal(Executive Officer)Matthew Frankel(Executive Officer)Arnon Aharon(Executive Officer)

Board seatStephen Squinto· per SEC Form D

Co-investorsAltium Capital

Clementia PharmaceuticalsJun 2015SEC filingmedium confidence

BiotechDorval

Francois Nader(Director)Donna Roy Grogan(Executive Officer)Jean-Francois Pariseau(Executive Officer, Director)Michael Singer(Executive Officer)David P. Bonita(Director)inRobert Heft(Director)

Board seatDavid Bonita· per SEC Form D · $60M raise · filed Jul 2015

Curevo, Inc.Mar 2025SEC filingmedium confidence

Bothell, US

Board seatTal Zaks· per SEC Form D · $84.8M raise · filed Mar 2025

Enlaza Therapeuticsenlazatx.com inAug 2025SEC filingmedium confidence

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)

BoardMarcos Milla(Director)Jay Lichter(Director)Tighe Reardon(Executive Officer)

Board seatStephen Squinto· per SEC Form D · $15M raise · filed Sep 2025

Co-investorsFrazier Life Sciences Lightspeed Venture Partners Samsara BioCapital Avalon BioVentures Pappas Capital Pfizer Venture Investments

FORE US BioApr 2025SEC filingmedium confidence

BiotechPhiladelphia, US

William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)

BoardGiovanni Mariggi(Director)inMatthew Foy(Director)

Board seatErez Chimovits· per SEC Form D · $46M raise · filed May 2025

Co-investors3B Future Health Fund Medicxi

Gemini TherapeuticsApr 2016

BiotechCambridge, US

James McLaughlin(Executive Officer, Director)

BoardJean George(Director)Jason Rhodes(Director)

Board seatCarl Gordon· per SEC Form D

Co-investorsLightstone Ventures Atlas Venture

Gennao Bio inMay 2021SEC filingmedium confidence

BiotechPennington, US

Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)Dale Ludwig(Mr. Ludwig is the Chief Scientific Officer)Anuj Goswami(Mr. Goswami is the General Counsel and Secretary)Claudine Prowse(Ms. Prowse is the Chief Financial Officer)Gary Sender(Director)Julie Hambleton(Director)

Board seatChau Khuong· per SEC Form D · $55M raise · filed Dec 2021

Igenica BiotherapeuticsJan 2015SEC filingmedium confidence

BiotechBurlingame, US

John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)

BoardJohn Diekman(Director)inDavid Goeddel(Director)Robert Schreiber(Director)

Board seatCarl Gordon· per SEC Form D · $6.3M raise · filed Jan 2015

Co-investors5AM Ventures The Column Group

Ikena Oncology, Inc.Jul 2025SEC filingmedium confidence

BiotechBoston, US

Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)

BoardOtello Stampacchia(Director)in

Board seatIain DukesDavid Bonita· per SEC Form D · $75M raise · filed Jul 2025

Co-investorsAtlas Venture Biotechnology Value Fund Foresite Capital Omega Funds RTW Investments L.P.

Inspire Medicalinspiresleep.com in 𝕏Oct 2016SEC filingmedium confidence

Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective.

Digital HealthHealthtechMedical DevicesGolden Valley, US

Timothy Herbert(Executive Officer, Director)Tim Herbert(Founder)inGlen Nelson(Director)Benjamin Pless(Director)Mark Fletcher(Director)Edward Shuck(Director)

Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016

Co-investorsAmzak Health APERTURE Venture Partners US Venture Partners

Neurogastrxneurogastrx.com inJun 2021

Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.

BiotechHealthtechWoburn, US

Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)

BoardDAVID ALLISON(Director)

Board seatKevin KochKlaus Veitinger· per SEC Form D

Co-investors5AM Ventures Samsara BioCapital venBio Partners Vivo Capital venBio Global Strategic Westlake Village BioPartners

Noctrix Healthnoctrixhealth.comJan 2021 · $40M

Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.

Digital HealthMedical DevicesWellness & FitnessPleasanton, US

Shri Raghunathan(Founder)in

Board seatChau Khuong· per SEC Form D

Co-investorsAngelini Ventures Blue Venture Funds Treo Ventures, Llc Zühlke Ventures Bridge Bank Sandbox Clinical Ventures +1 more

Perfuse Therapeuticsperfusetherapeutics.com inMar 2019

Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.

BiotechMedical DevicesSan Francisco, US

BoardChristy Shaffer(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)in

Board seatChau Khuong· per SEC Form D

Co-investorsAccess Biotechnology Catalio Capital Management, LP Hatteras Venture Partners LAV Lilly Asia Ventures Hatteras

Pieris PharmaceuticalsJun 2016SEC filingmedium confidence

BiotechBoston, US

Darlene Deptula-Hicks(Executive Officer)Stephen S. Yoder(Executive Officer, Director)Darlene M. Deptula-Hicks(Acting Chief Financial Officer)Christina Takke(Director)

BoardSteven Prelack(Director)

Board seatChau Khuong· per SEC Form D · $16.5M raise · filed Jun 2016

Prevail TherapeuticsMar 2018SEC filinghigh confidence

HealthtechNew York, US

ASA ABELIOVICH(Executive Officer, Director)

Board seatCarl GordonPeter ThompsonMona Ashiya· per SEC Form D · $65M raise · filed Mar 2018

Promentis Pharmaceuticalspromentispharma.comDec 2019SEC filingmedium confidence

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.

BiotechHealthtechMental HealthMilwaukee, US

David Baker, PhD(Director)Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)

Board seatKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019

Co-investorsAisling Capital F-Prime Capital

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Aug 2015SEC filingmedium confidence

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inNeil Exter(Director)inTodd Foley(Director)

Board seatJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments Third Rock Ventures

Sparrow Pharmasparrowpharma.com in 𝕏Jul 2025

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.

BiotechHealthtechMedical DevicesPortland, US

Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)

BoardJonathan Root(Director)inNiall O'Donnell(Director)inZach Scheiner(Director)in

Board seatKlaus Veitinger· per SEC Form D

Co-investorsRA Capital RiverVest Venture Partners US Venture Partners

SpringWorks TherapeuticsMar 2019SEC filinghigh confidence

HealthtechStamford, US

Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)

BoardDeval Patrick(Director)Carl L Gordon(Director)in

Board seatStephen SquintoCarl Gordon· per SEC Form D · $125M raise · filed Apr 2019

Co-investorsBain Capital Life Sciences Pfizer Venture Investments

Symbiomix TherapeuticsApr 2016SEC filingmedium confidence

BiotechNewark, US

Robert Jacks(Executive Officer)Joseph Amprey(Executive Officer)

BoardThomas Beck(Director)Ben Auspitz(Director)

Board seatRishi GuptaKlaus Veitinger· per SEC Form D · $6M raise · filed May 2016

Theseus Pharmaceuticalstheseusrx.comJun 2018

BiotechCambridge, US

William C. Shakespeare(Director)

BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)

Board seatCarl Gordon· per SEC Form D

Co-investorsForesite Capital Longitude Capital Nextech Invest

Thrombolexthrombolex.com in 𝕏Feb 2026

Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.

BiotechHealthtechMedical DevicesKingston, US

Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)John Cerminaro(Executive Officer)Michael J. Cerminaro(Executive Officer, Director)Marvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)

Board seatDavid Bonita· per SEC Form D

Treeline Biosciencestreeline.bioAug 2025

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechMedical DevicesWatertown, US

Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in

BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in

Board seatDavid Bonita· per SEC Form D

Co-investorsAisling Capital ARCH Venture Partners Casdin Capital Fidelity Investments GV (Google Ventures)Rock Springs Capital +1 more

Tricidatricida.comJul 2016SEC filingmedium confidence

BiotechSouth San Francisco, US

Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)

BoardSandra Coufal(Director)Robert Alpern(Director)

Board seatKlaus VeitingerDavid Bonita· per SEC Form D · $55.5M raise · filed Jul 2016

Co-investorsAvoro Capital Advisors Longitude Capital

Vanqua BioAug 2021

BiotechChicago, US

Rand Sutherland(Director)James Sullivan(Executive Officer, Director)in

BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)

Board seatJonathan SilversteinStephen SquintoMona Ashiya· per SEC Form D

Co-investorsPontifax Venture Capital

Viewrayviewray.com in 𝕏Dec 2014SEC filingmedium confidence

ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.

HardwareHealthtechMedical DevicesOakwood Village, US

James F. Dempsey(Executive Officer, Director)James Dempsey(Secretary of the Issuer.)David Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Chris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)

Board seatDavid Bonita· per SEC Form D · filed Aug 2015

Co-investorsAisling Capital F-Prime Capital

Adarxadarx.com in

ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes.

BiotechMedical Devices

Co-investorsTCG Crossover Vivo Capital

Adcendo ApSadcendo.com

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital Novo Holdings Pontifax Venture Capital RA Capital +2 more

Adimabadimab.com in

Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners.

AI & Machine LearningBiotechDeep Tech

Co-investorsGrandBanks Capital LaunchCapital Lux Capital Premji Invest SV Health Investors Mithril Capital Management +1 more

Aduro Biotech

BiotechBerkeley, US

Thomas Dubensky(Executive Officer)Dirk G. Brockstedt(Executive Officer)Stephen Isaacs(Executive Officer, Director)Jennifer Lew(Executive Officer)Gregory W. Schafer(Executive Officer)Gregory Schafer(Executive Officer)

Co-investorsForesite Capital Franklin Templeton

Advancedenzymesadvancedenzymes.com

Advanced Enzymes manufactures enzymes for a range of industries including human health and nutrition, animal nutrition, baking, food and grain processing, dairy, textile, and leather processing.

BiotechFoodTechNew Materials

Aerin Medicalaerinmedical.com in 𝕏Feb 2025

Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.

HealthtechMedical DevicesMountain View, US

Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Fred Dinger(Executive Officer, Director)

Co-investorsLaunchCapital Questa Capital Targeted Technology Funds Ally Bridge Group Horizon

Aige010aige010.com

Aimsindiaaimsindia.com in 𝕏

Asian Healthcare (AIMS) operates a network of hospitals across India, offering specialized clinical services such as robotic surgery, cardiac procedures, neurology, orthopedics, and maternity care.

HealthtechMedical Devices

AirNexisairnexis.com

Co-investorsFrazier Life Sciences Longitude Capital

Airstripairstrip.com in 𝕏

AirStrip provides mobile and web applications that consolidate clinical data from EMRs, in-room monitors, and medical devices into a single view, giving clinicians remote access to patient waveforms, ECGs, and vital signs.

Digital HealthHealthtechMedical DevicesSan Antonio, US

Alan Portela(Executive Officer, Director)David Sachs(Director)Charles Kim(Director)Robert Morse(Director)JF Lancelot(Executive Officer)

BoardPatrick Soon-Shiong(Director)

Ak Medicalak-medical.net

AK Medical (爱康医疗) develops orthopedic implants and technologies, including metal 3D-printed implants with trabecular bone-like structures, Supravit HA plasma vacuum spray coatings, surgical planning software and robotics, and personalized custom orthopedic solutions.

HardwareHealthtechMedical Devices

Co-investorsDecheng Capital

Alentisalentis.ch in

Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis.

BiotechHealthtech

Co-investorsAvego BioScience Capital BioMedPartners Catalio Capital Management, LP Frazier Life Sciences Jeito Capital Longitude Capital +3 more

Alterome Therapeutics, Inc.alterome.com inDec 2021

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)

BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in

Co-investorsCanaan Partners Nextech Invest Vida Ventures Digitalis Ventures NVIDIA

Altis Labsaltislabs.com in 𝕏

Altis Labs provides tools for analyzing medical imaging data to help biopharma sponsors gain insight during drug development, and supports clinicians and scientists conducting medical imaging research.

AI & Machine LearningBiotechMedical Devices

Felix Baldauf-Lenschenin

Co-investorsCreative Destruction Lab (CDL)Debiopharm Innovation Fund Fusion Benchstrength Partners

Anchordxanchordx.com

AnchorDx (基准医疗) develops ctDNA methylation high-throughput sequencing technology for early cancer detection, using blood and urine samples to cover more than 70% of high-incidence cancers including lung, breast, digestive-system and urinary-system cancers.

BiotechDigital HealthHealthtech

Co-investorsMarathon Venture Partners

Angitia Bioangitiabio.com

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and other serious diseases.

Biotech

Co-investorsFrazier Life Sciences RA Capital Frazier

Arcatronarcatron.com 𝕏

Arcatron designs and sells mobility and assistive products under the Frido brand, including electric and manual wheelchairs, mobility scooters, transfer lifts, walking aids, shower and hygiene aids, and bath mats.

ConsumerE-commerceMedical Devices

Dewaj Baruah(Founder)in

Architect Therapeuticsarchitecttherapeutics.com

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.

BiotechDeep Tech

Jin-Quan Yu(Founder)in

Co-investorsFrazier Life Sciences

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LP Foresite Capital General Catalyst HongShan Capital Group LAV Lilly Asia Ventures +2 more

Ars Pharmaars-pharma.com in 𝕏

ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)

BoardJonathan Leff(Director)

Co-investorsNextech Invest RA Capital SR One Capital Management

Avedroavedro.com in 𝕏acquired by Glaukos

BiotechHealthtechMedical DevicesWaltham, US

David F. Muller(Executive Officer, Director)Brian J. Roberts(Executive Officer)Rhonda J. Bracey(Executive Officer)

BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in

Co-investorsAPERTURE Venture Partners LAV Lilly Asia Ventures SCP Vitalife Partners Third Point Ventures HealthQuest Capital

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)Quan Capital +3 more

Avernatxavernatx.com in

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechMedical Devices

Thomas M. Barnes(CEO & Board Member)

Co-investorsDeep Insight Delos Capital Novartis Venture Fund

Avicedarxavicedarx.com in 𝕏

Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration.

BiotechHealthtech

Co-investorsJeito Capital Longitude Capital Digitalis Ventures

Avitideavitide.com inacquired by Repligen

Advanced ManufacturingBiotechHardwareLebanon, US

Tillman Gerngross(Director)Warren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Isett(Executive Officer, Director)Jonathan Sheller(Executive Officer)Errik Anderson(Director)

Co-investorsSV Health Investors Mithril Capital Management Sands Capital Ventures SV Life Sciences

Azuraophthalmicsazuraophthalmics.com in 𝕏

Azura Ophthalmics develops first-in-class keratolytic-based therapies for lid margin and ocular surface diseases, combining ophthalmologic and dermatologic approaches to treat underserved ocular indications.

BiotechHealthtechMedical Devices

Baili Pharmbaili-pharm.com

Bhtherapeuticsbhtherapeutics.com

BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.

Biotech

Co-investorsVivo Capital

Bionovapharmabionovapharma.com

Bonovo Orthobonovo-ortho.com

Braveheartbraveheart.bio in

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

Travis Murdoch, M.D.(Chief Executive Officer and Board Director)

Co-investorsAndreessen Horowitz Frazier Life Sciences

By Humabio-beat.com in 𝕏

Biobeat offers a wearable chest-patch device paired with a mobile app for 24-hour ambulatory blood pressure monitoring to confirm or unmask hypertension.

Digital HealthHealthtechMedical Devices

Arik B.(Founder)in

Co-investorsAlly Bridge Group Raptor Group

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite Capital Samsara BioCapital TCG Crossover Third Rock Ventures venBio Partners Vida Ventures

Carrot Fertilityget-carrot.com in 𝕏

Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.

FemTechHealthtechSan Francisco, US

Asima Ahmad(Founder/CMO)inTammy Sun(Founder)in

Co-investorsAll Turtles Aurum Backstage Capital Core Venture Capital CRV (Charles River Ventures)Expansion Venture Capital +8 more

Cellipontcellipont.com in 𝕏

Cellipont Bioservices is a contract development and manufacturing organization (CDMO) that provides cGMP cell therapy process development, analytical, and commercial manufacturing services, including CAR-T, from its facility in The Woodlands, Texas.

Advanced ManufacturingBiotechHealthtechThe Woodlands, US

Cerecor Inc.avalotx.com in

Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.

BiotechMedical DevicesBaltimore, US

Blake M. Paterson(Executive Officer, Director)Mariam Morris(Executive Officer)Ronald Marcus(Executive Officer)Uli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)James Vornov(Executive Officer)

Co-investorsNew Enterprise Associates (NEA)PETRICHOR SCION THERAPEUTICS

Charmcharm.sh 𝕏Sep 2025 · $80M

Charm develops open-source tools and libraries for building glamorous command-line interfaces and terminal user experiences, including CLI frameworks, UI components, and integrations with language models.

Developer Tools

Co-investorsBetaworks Cavalry Ventures Gradient Ventures LOWERCARBON Lowercarbon Capital BootstrapLabs +5 more

Charmwithcharm.appSep 2025 · $80M

Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.

ConsumerCrypto & Web3FintechSocialNew York City, US

Gray Newfield(Founder)inNoah Newfield(Founder)in

Co-investorsY Combinator 468 Capital BootstrapLabs Cavalry Ventures Fuel Capital Gradient Ventures +3 more

Charmcharm.land 𝕏Sep 2025 · $80M

Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.

Developer Tools

Co-investorsMotive Force NAP Cavalry Ventures Fuel Capital Gradient Ventures Khosla Ventures +2 more

CHARM Therapeuticscharmtx.com in

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)

BoardRishi Gupta(Director)Nihal Sinha(Director)inMuzammil Mansuri(Director)Gary Glick(Director)

Co-investorsF-Prime Capital New Enterprise Associates (NEA)SR One Capital Management Axial VC NVentures

Civitas Therapeuticscivitastherapeutics.comAug 2014

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)

BoardROB HOPFNER(Director)

Co-investorsCanaan Partners Sofinnova Ventures Bay City Capital Longitude Capital RA Capital

Cleave Biosciencescleavetherapeutics.com

BiotechBurlingame, US

Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)

BoardAlfred Scheidegger(Director)inPeter Thompson(Director)Carol Gallagher(Director)

Co-investorsAstellas Venture Management LLC New Enterprise Associates (NEA)Nextech Invest 5AM Ventures Clarus Ventures Osage University Partners +1 more

Convergentconvergent.org inMay 2023 · $90M

Convergent provides an AI simulation platform for enterprise training and skill development.

AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB

Co-investorsTechstars Andreessen Horowitz RA Capital

Convergent TherapeuticsMay 2023 · $90M

BiotechCambridge, US

Philip Kantoff(Executive Officer, Director)Neil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)Alexander Brown(Executive Officer)

BoardJake Simson(Director)inTal Zaks(Director)

Co-investorsInvus RA Capital

Convergentrxconvergentrx.com in 𝕏

Convergent Therapeutics develops radioantibody (targeted alpha-particle radiopharmaceutical) therapies for cancer patients, including its lead candidate CONV01-α for metastatic castration-resistant prostate cancer.

BiotechHealthtech

Corteriapharmacorteriapharma.com in

Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.

BiotechHealthtech

Co-investorsFountain Healthcare Partners Invivo Capital Partners Jeito Capital Kurma Partners LifeArc Ventures V-Bio Ventures

Corvuspharmacorvuspharma.com in

Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(Executive Officer, Director)Leiv Lea(Executive Officer)Terry G. Gould(Director)

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Director)

Co-investorsAvoro Capital Advisors Foresite Capital

Creaternacreaterna.com

Landos Technology (朗来科技) is a clinical-stage drug discovery and development company with a pipeline of novel small-molecule therapies for indications including hypertension, chronic heart failure, IgA nephropathy, FSGS, chronic cough, idiopathic pulmonary fibrosis, and autoimmune diseases such as rheumatoid arthritis and psoriasis.

BiotechHealthtechWuhan, CN

Co-investorsVivo Capital Lilly Asia Ventures

Creditpharmacreditpharma.com

Crineticscrinetics.com in 𝕏

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

Biotech

Co-investors5AM Ventures RA Capital

Curevo Vaccinecurevovaccine.com inMar 2025 · $110M

Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.

BiotechHealthtech

Co-investorsAdjuvant Capital RA Capital Sanofi Ventures HBM Healthcare Investments Janus Henderson Investors Medicxi

Cyruscyrus.app in 𝕏Acquired

Cyrus provides a mobile app for personal cybersecurity and financial protection, offering account monitoring, dark web scanning, credit monitoring across three bureaus, VPN services, and fraud support for consumers.

ConsumerCybersecurityDigital Health

Co-investorsResolute Ventures SPRINGROCK VENTURES Rainfall Ventures The Fintech Fund Trinity Ventures

Cyrusbiocyrusbio.com in 𝕏

Cyrus Bio is a computational drug discovery company that uses protein design, deep mutagenesis, and modeling algorithms to engineer naturally occurring proteins into therapeutics.

AI & Machine LearningBiotechDeep TechSeattle, US

Javier Castellanos(Executive Officer, Director)Yifan Song(Executive Officer, Director)

BoardLucas Nivon(Executive Officer, Director)

Co-investorsAnzu Partners Argonautic Ventures iSelect Fund SPRINGROCK VENTURES Strawberry Creek Ventures The W Fund +2 more

CytomXcytomx.com in 𝕏

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtech

Sean A. McCarthy(Chief Executive Officer and Chairman)Marcia P. Belvin(SVP, Chief Scientific Officer)Dawn Benson(SVP, Quality and Product Manufacturing)Wayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)Chris Ogden(Chief Financial Officer)

Co-investorsCanaan Partners Longitude Capital Pfizer Venture Investments

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Executive Officer, Director, Promoter)Peter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)

BoardRishi Gupta(Director)in

Co-investorsAV8 Ventures Foresite Capital Illumina Ventures Menlo Ventures Open Field Capital OUP (Osage University Partners)+3 more

Dihdih.com in

DIH develops, manufactures, and integrates advanced rehabilitation technology and solutions across the continuum of care, serving hospitals, clinics, research institutions, and home settings.

HardwareHealthtechMedical Devices

Dimension TherapeuticsApr 2015

Cambridge, US

Annalisa Jenkins(Executive Officer, Director)

BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)

Co-investorsF-Prime Capital New Leaf Venture Partners

Dlabscidlabsci.com

Dmhxmdmhxm.com

大米和小米 (DMHXM) operates a network of over 80 directly-run centers across more than 30 Chinese cities providing in-person early intervention and rehabilitation therapy for children with autism and developmental disorders, staffed by BCBA/BCaBA-certified therapists and experienced supervisors.

Digital HealthHealthtechWellness & FitnessShenzhen, CN

Echealthcareechealthcare.com in

EC Healthcare offers aesthetic and medical services, including medical aesthetic products and treatments delivered with medical technology and physician involvement.

ConsumerHealthtechWellness & Fitness

Eddingpharmeddingpharm.com

Edgewise Therapeuticsedgewisetx.com in 𝕏

Edgewise Therapeutics develops novel therapeutics for serious cardiovascular muscle diseases, including hypertrophic cardiomyopathy (HCM) and heart failure.

BiotechDigital Health

Co-investorsUS Venture Partners

Eileanthereileanther.com

Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies for hematologic malignancies (blood cancers) that target drivers of cancer resistance and escape mutations.

BiotechHealthtech

Electra Therapeuticselectra-therapeutics.com inOct 2025

Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)

BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)

Co-investorsRA Capital Westlake Village BioPartners NVIDIA

Enterohealthcareenterohealthcare.com in

Entero Healthcare Solutions Limited is an Indian healthcare company that filed a Draft Red Herring Prospectus with SEBI in September 2023 for a public offering.

Healthtech

Prem Sethi(Founder)in

Enyo Pharmaenyopharma.com in 𝕏

ENYO Pharma is a clinical-stage biopharmaceutical company developing therapeutics for patients with impaired kidney function.

BiotechMedical Devices

Co-investorsAndera Partners Sofinnova Partners Bpifrance

Epigenictxepigenictx.com in

Epigenic Therapeutics develops epigenetic medicines using an Epigenetic Modulator platform that combines nuclease-inactivated dead Cas proteins with epi-enzymes to control gene expression without cutting or altering DNA.

BiotechDeep TechHealthtech

Chloe You(Chief Medical Officer)Kelly Shi(Chief Financial Officer)

Co-investorsQiming Venture Partners

Ethrisethris.com

Eurolifehealthcareeurolifehealthcare.com

Evox Therapeuticsevoxtherapeutics.com in 𝕏

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.

BiotechDeep Tech

Co-investorsOxford Science Enterprises Panacea Venture Cowen Healthcare Investments GV (Google Ventures)REDMILE

Evozyneevozyne.com inSep 2023 · $81M

Evozyne is an AI-native biotech that designs de novo therapeutic proteins using EvoGen, a machine learning engine, and EvoLab, a high-throughput experimental facility that synthesizes and tests candidate proteins.

AI & Machine LearningBiotechDeep TechChicago, US

Aris Theologis(Executive Officer, Director)Darien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Rama Ranganathan(Executive Officer, Director)

BoardJeffrey S. Aronin(Director)Antonio Gracias(Director)in

Co-investorsParagon Biosciences LLC Fidelity Investments NVentures NVIDIA Valor Equity Partners

Forefore.bio in 𝕏

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsLG Technology Ventures Novartis Venture Fund Pontifax Venture Capital Windham Capital Partners Medicxi SymBiosis

Fortebiorxfortebiorx.com

Forward Txforward-tx.com in

Forward Therapeutics is a biotech company developing a pipeline of oral small molecule therapies targeting inflammation-driven diseases.

Biotech

Fridomyfrido.com in 𝕏Feb 2024

Frido is a consumer brand offering ergonomic and comfort products such as insoles, footwear, cushions, pillows, mattress toppers, and maternity and baby care items, sold direct to consumers and in bulk to businesses.

ConsumerDirect to ConsumerWellness & Fitness

Ganesh Sonawane(Founder)in

Fronteratherapeuticsfronteratherapeutics.com in

Frontera Therapeutics is a clinical-stage gene therapy company developing treatments for large-market and rare diseases across ophthalmology, cardiology, and neurology.

BiotechHealthtech

Fusmobilefusmobile.com in 𝕏

FUS Mobile develops the Neurolyser XR, a non-invasive, fluoroscopy-guided ablative therapy platform for treating chronic low back pain caused by arthritis of the vertebral facet joints.

HardwareHealthtechMedical Devices

Co-investorsAtlanta Technology Angels

Futurxfuturx.co.il

Galecto Biotechgalecto.com in

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.

BiotechMedical Devices

Jennifer Jarrett(Chief Executive Officer & Board Director)Sherwin Sattarzadeh(Chief Operating Officer)Becker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)Jim Baker(Chief Corporate Affairs Officer)Brian Burkavage(Senior Vice President, Finance)

Co-investorsEIR Ventures Hadean Ventures M Ventures SEED Capital Denmark Sunstone Capital Ysios Capital +1 more

Gaushgaush.com

Co-investorsHighlight Capital

Gelesisgelesis.com in

Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health.

BiotechDigital HealthHealthtechWellness & FitnessBoston, US

Yishai Zohar(Director, President, and Chief Executive Officer)Elliot Maltz(Treasurer)

BoardJohn LaMattina(Director)Elon Boms(Director)inMeghan Fitzgerald(Director)Robert Forrester(Director)

Co-investorsLaunchCapital Capstar Ventures Invesco Vitruvian Partners

Gennaogennao.com

Genocurygenocury.com

Good Doctor Cloud Healthhys.cn

Gracellbiogracellbio.com in

Gracell develops CAR-T cell therapies aimed at delivering fast, deep, and durable responses for patients with cancer and autoimmune disease.

BiotechHealthtech

Co-investorsLAV Lilly Asia Ventures

Harvestiroharvestiro.com in

Harvest Integrated Research Organization (HiRO) is a full-service global contract research organization (CRO) providing end-to-end clinical trial services, including clinical data science, biometrics, site engagement, medical oversight, safety monitoring, regulatory guidance, and medical writing.

BiotechDigital HealthHealthtech

Helicorehelicore.comJan 2025

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.

BiotechHealthtech

Co-investorsLongitude Capital Versant Ventures Wellington Management

Hysyylhysyyl.com

Iambiciambic.ai in

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.

AI & Machine LearningBiotechDeep TechSan Diego, US

Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in

Co-investorsAbingworth Ascenta Capital Catalio Capital Management Alumni Ventures Catalio Capital Management, LP Coatue Management +4 more

Iecureiecure.com

iECURE develops in vivo genetic therapies using targeted gene insertion and genome editing to treat rare neurometabolic disorders, initially focusing on liver-centered metabolic conditions.

BiotechMedical Devices

Ikenaoncologyikenaoncology.com in 𝕏

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.

BiotechHealthtechSan Diego, US

Co-investorsAtlas Venture

Immune Pathimmune-path.com

Co-investorsQiming Venture Partners

Innvolutioninnvolution.com

Insilico Medicineinsilico.com in 𝕏

Insilico Medicine applies computational and AI-based modeling to drug design and problems such as protein folding for pharmaceutical research and development.

AI & Machine LearningBiotechHealthtechHong Kong

Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)

BoardNisa Leung(Director)Lennart Lee(Director)James Mellon(Director)

Co-investorsB Capital Group B4 Capital BOLD Longevity F-Prime Capital Gestio Capital LAV +5 more

Inventisbioinventisbio.com in

InventisBio (益方生物) is a biopharmaceutical company that develops small-molecule drugs, including candidates targeting KRAS G12C for lung and pancreatic cancer and treatments for moderate-to-severe plaque psoriasis.

BiotechHealthtechShanghai, CN

Xing Dai(Founder)in

Co-investorsLAV Lilly Asia Ventures Qiming Venture Partners

Iswaryafertilityiswaryafertility.com

Janux Therapeuticsjanuxrx.com in 𝕏

Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases.

BiotechMedical DevicesLa Jolla, US

David Campbell, Ph.D.(Executive Officer, Director)Tighe Reardon(Executive Officer)

BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)Stefan Heller(Director)

Co-investorsAvalon BioVentures Samsara BioCapital

Jinxin Fuxing Eldercarejx-care.com

锦欣康养 is a subsidiary of Jinxin Medical Group that operates elderly care services combining medical treatment and senior living, including institutional care, home and community care, geriatric medicine, rehabilitation, and nursing.

HealthtechLongevityWellness & FitnessChengdu, CN

Jxfxkyjxfxky.com

Kapivakapiva.in 𝕏

Kapiva is an Ayurveda-based wellness brand that sells health and nutrition products online, with ranges covering sugar management, fitness, energy, heart and liver health, skin and hair, and women's health.

ConsumerDirect to ConsumerWellness & Fitness

Co-investorsTrifecta Capital Advisors Vertex Ventures Sea Management Pte. Ltd.3one4 Capital Vertex Growth

Kartostherakartosthera.com in 𝕏

Kartos Therapeutics develops targeted oral therapeutics for cancer, including Navtemadlin, an MDM2 inhibitor aimed at the MDM2-p53 interaction to treat selected solid tumors and hematological malignancies.

BiotechHealthtech

Co-investorsSR One Capital Management

Kerostxkerostx.com in

Keros Therapeutics develops therapies targeting the transforming growth factor-beta (TGF-ß) family of proteins to treat disorders linked to dysfunctional TGF-ß signaling.

Biotech

Co-investorsPontifax Venture Capital

Koya Medicalkoyamedical.com inDec 2020

Koya Medical develops wearable compression therapy devices, including its Dayspring system, for treating conditions such as lymphedema, chronic venous insufficiency, and deep vein thrombosis.

HardwareHealthtechMedical DevicesOakland, US

Anand Doraiswamy(Executive Officer, Director)

BoardJosh Baltzell(Director)inJan Garfinkle(Director)in

Co-investorsAphelion Capital Arboretum Ventures Scientific Health Development Zühlke Ventures

Kumquat Bioscienceskumquatbiosciences.com inFeb 2021

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)Lynn Yang(Director)

BoardCarl Gordon(Director)in

Co-investorsEcoR1 Capital Roche Venture Fund

Laekna Therapeuticslaekna.com

Develops innovative therapies for cancer and liver diseases.

Co-investorsHB Ventures Infinity Capital

Laeknatplaeknatp.com

Laxmidentallaxmidental.com

Lealleal.co in

Leal 360 is a retail-focused customer platform for LATAM that combines a CDP, campaign automation, loyalty programs, and NPS with an AI decision engine, connecting to a business's POS to turn purchase data into personalized marketing and loyalty actions.

AI & Machine LearningMarketing TechRetail Tech

Co-investorsAspira Capital Axon Partners Group Capria Ventures Fuel Venture Capital LEAP Global Partners Salkantay Ventures +1 more

Lealtxlealtx.com

Leal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's.

BiotechMedical DevicesWorcester, US

Co-investorsNewpath Partners

Lexeotxlexeotx.com in

LEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease.

BiotechHealthtech

Co-investorsLongitude Capital

Lifecelllifecell.in in 𝕏

LifeCell offers diagnostic lab tests, stem cell banking, allografts, and skincare products for individuals and families.

BiotechConsumerHealthtechChennai, IN

LogicBiologicbio.com in 𝕏

LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.

BiotechHealthtechCambridge, US

Leszek Lisowski(Executive Officer, Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)

BoardErez Chimovits(Director)

Co-investorsAndera Partners Pontifax Venture Capital Arix Bioscience

Lomondtherlomondther.com in 𝕏

Lomond Therapeutics is a small molecule oncology drug discovery company developing precision hematology medicines that target resistant escape mutations in hematological cancers.

BiotechHealthtech

Lupengbiolupengbio.com

Lupeng Bio is a biotechnology company focused on the design and development of new anti-tumor (oncology) drugs.

BiotechHealthtech

Co-investorsLAV Lilly Asia Ventures

Lycia Therapeuticslyciatx.com in 𝕏Jun 2026 · $75M

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)

Co-investorsREDMILE Versant Ventures BAM Elevate Franklin Templeton HBM Healthcare Investments Invus +4 more

Magenta Medicalmagentamed.com in 𝕏

MagentaMed develops the Elevate percutaneous Left Ventricular Assist Device (pLVAD), a low-profile, high-flow arterial pump for temporary mechanical circulatory support.

HardwareHealthtechMedical Devices

Co-investorsALIVE Israel HealthTech Fund Fresenius Medical Care Ventures New Enterprise Associates (NEA)RA Capital

Marksanspharmamarksanspharma.com

Marksans Pharma is an Indian pharmaceutical company that researches, manufactures, and markets finished dosage pharmaceutical formulations.

BiotechHealthtech

Browse all 284 investments with full details →

▶84 more tracked companies

MBX MBX Biosciences Mdclone MDxHealth Medpharm Mendra MinervaXMinghuipharmaMirador TherapeuticsMobileodtMondegobio Mybinxhealth Myriad NanotronicsNerre TherapeuticsNeurelis NewmedNorchem PharmaNucleix Nucleusrad Odyssey Therapeutics Ottimopharma Pathai PathalysPeesafePic Therapeutics Pinnacle PMV Pharma Principia Biopharma Prolynxinc Propeller ProVerumPulnovomedQuantxbio RadiuspharmRampartbioRAPT Therapeutics RayThera ReCode TherapeuticsReliabiotechRenasant BioReparerxSeroba Lifesciences Sidewinderbio Sikkasoft Sitala SiteOne TherapeuticsSneuroSpectronrx Stairmed Star Sportsmed Star Therapeutics StarlingoncologyStratustxSurakshanet Tandemai TELA BioTendfoTerremotobio The Oncology Institute TigerConnect Topaz Tx Treeline Treeline Trisaluslifesci TriveniTrunativTurnstone Biologics Tyto Care Uquifa Vanquabio Velosbio Velsera Verdiva Bio VerricaVivacta BioVvardis Whaleimaging Windward Bio Yarrowbioscience ZaiZenteratxZionpharmaZyloxtb

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 38

IPOs and acquisitions across the tracked portfolio

Q32 BioNASDAQ: QTTBScribe TherapeuticsNASDAQ: SCTXAadi BioscienceNASDAQ: WHWKAdicet BioNASDAQ: ACETArvinas Holding Co. LLCNASDAQ: ARVNCalcimedicaNASDAQ: CALCCompass TherapeuticsNASDAQ: CMPXImaraNASDAQ: ELVNKeros TherapeuticsNASDAQ: KROSMirna TherapeuticsOTC: SYBXNextCureNASDAQ: NXTCPrelude TherapeuticsNASDAQ: PRLDSI-BONENASDAQ: SIBNSpruce BiosciencesNASDAQ: SPRBSynlogicOTC: SYBXAdaptive BiotechnologiesNASDAQ: ADPTAlumisNASDAQ: ALMSAura BiosciencesNASDAQ: AURAAvita MedicalNASDAQ: RCELBioAge LabsNASDAQ: BIOABiomXNYSE: PHGECaris Life SciencesNASDAQ: CAICullinan TherapeuticsNASDAQ: CGEMDisc MedicineNASDAQ: IRONEmergent BiosolutionsNYSE: EBSEnliven TherapeuticsNASDAQ: ELVNInsmedNASDAQ: INSMInspireMDNASDAQ: NSPRNeuroPaceNASDAQ: NPCEOncology InstituteNASDAQ: TOIShattuck LabsNASDAQ: STTKSonendoOTC: SONXTELA BioNASDAQ: TELATrawspharmaNASDAQ: TRAWUpstream BioNASDAQ: UPBVerastemNASDAQ: VSTMAvedroacq. by GlaukosAvitideacq. by Repligen

Portfolio news

latest coverage across their companies

Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM

Cullinan Therapeutics · marketbeat.com · Aug 21, 2026

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies · barchart.com · Aug 21, 2026

This Torrance Startup Just Raised $1B to Mass-Produce Hypersonic Missiles - dot.LA

Leal · dot.la · Aug 21, 2026

Enliven Therapeutics (NASDAQ:ELVN) Earns Outperform Rating from Analysts at William Blair - Ticker Report

Enliven Therapeutics · tickerreport.com · Aug 21, 2026

LogicBio Therapeutics (OTCMKTS:LOGC) Hits New 52-Week High – Should You Buy? - Markets Daily

LogicBio · themarketsdaily.com · Aug 20, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

Ars Pharma · prnewswire.com · Aug 20, 2026

18,382 Shares in Inspire Medical Systems, Inc. $INSP Acquired by GSA Capital Partners LLP - Markets Daily

Inspire Medical · themarketsdaily.com · Aug 19, 2026

Aura Biosciences (NASDAQ:AURA) Shares Up 6.5% – Here’s What Happened - Ticker Report

Aura Biosciences · tickerreport.com · Aug 18, 2026

Fund performance · per public LP disclosures · 10

as of Sep 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
OrbiMed Private Investments IX, LPLPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board, Kern County Employees' Retirement Association	2022	—	29.3%	1.16x	0.21x
OrbiMed Royalty & Credit Opportunities IVLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System, Kern County Employees' Retirement Association	2022	—	14.1%	1.28x	0.25x
OrbiMed Private Investments VIII, L.P.LPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board	2020	—	6.9%	1.19x	0.30x
OrbiMed Royalty & Credit Opportunities III, LPLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System	2019	—	15.1%	1.20x	0.95x
OrbiMed Private Investments VILPs: Oregon Public Employees Retirement System	2015	—	13.0%	1.64x	1.18x
OrbiMed Private Investments VLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System	2013	—	38.2%	2.35x	2.14x
OrbiMed Private Investments IVLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, The Regents of the University of California +1 more	2009	—	31.8%	2.73x	2.72x
Orbimed Private lnvesuncnts IV, L PLPs: The Regents of the University of California	2009	—	36.2%	2.67x	0.45x
Orbimed Private Investments III, LPLPs: The Regents of the University of California	2006	—	18.1%	2.34x	1.48x
Orbimed Private lnvesunents Ill, LPLPs: The Regents of the University of California	2006	—	18.4%	2.32x	—

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has OrbiMed made?: OrbiMed has 205 tracked investments, 2 of which have exited via acquisition or IPO, including 12 dated in the last 24 months.
What stage does OrbiMed invest at?: OrbiMed invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is OrbiMed's typical check size?: OrbiMed typically writes checks of $1M – $75M.
What sectors does OrbiMed focus on?: OrbiMed focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is OrbiMed located?: OrbiMed is headquartered in New York, US.
Does OrbiMed lead rounds?: Yes, OrbiMed leads investment rounds.
Who does OrbiMed co-invest with?: OrbiMed most often shares deals with RA Capital, Foresite Capital, Frazier Life Sciences, among 218 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Geoffrey C. Hsu, CFA, General Partner, OrbiMed Advisors LLC

Biotechnology Innovation Organization · Geoffrey C. Hsu

Co-investors · 87

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 12

Imara NeuroPace Synlogic Avenzo Brenig Cerecor Inc.Charm CHARM Therapeutics Cleave Biosciences Magenta Medical MBX Biosciences Rhythm Pharmaceuticals

$200K – $40M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 12

Compass Therapeutics Insmed Adelabio Carrot Fertility CHARM Therapeutics Dimension Therapeutics Insilico Medicine Oncusp Therapeutics Promentis Pharmaceuticals Tandemai Turnstone Biologics Viewray

$3M – $10M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 11

BioAge Labs NextCure Synlogic Aerpio Therapeutics Arrivent Avenzo Civitas Therapeutics Oncusp Therapeutics Principia Biopharma Star Therapeutics Velosbio

$100K – $15M

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Both backed · 10

NextCure Arrivent Avedro Createrna Gracellbio Insilico Medicine Inventisbio Lupengbio Nucleix Perfuse Therapeutics

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 9

Disc Medicine Q32 Bio Synlogic Gemini Therapeutics Ikena Oncology, Inc.Ikenaoncology Renasant Bio Sionnatx Triveni

$500K – $1M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 9

Q32 Bio Curevo Vaccine MinervaX Mirador Therapeutics Odyssey Therapeutics Quantxbio ReCode Therapeutics Star Therapeutics Windward Bio

$5M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 9

Enliven Therapeutics Mirna Therapeutics NextCure Synlogic CytomX Enlaza Therapeutics ReCode Therapeutics Rhythm Pharmaceuticals SpringWorks Therapeutics

$5M – $20M

Samsara BioCapital

Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.

Both backed · 9

Alumis Upstream Bio Candid Therapeutics Delfi Diagnostics Enlaza Therapeutics Janux Therapeutics Neurogastrx Pathalys Principia Biopharma

Nextech Invest

Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.

Both backed · 8

Alumis Arvinas Holding Co. LLC Cullinan Therapeutics Alterome Therapeutics, Inc.Ars Pharma Cleave Biosciences PMV Pharma Theseus Pharmaceuticals

$648K – $3.2M

SR One Capital Management

SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.

Both backed · 7

Alumis Ars Pharma Avenzo CHARM Therapeutics Kartosthera Odyssey Therapeutics Windward Bio

▶75 more co-investors

5AM Ventures Vivo Capital Canaan Partners venBio Partners Avoro Capital Advisors Andreessen Horowitz US Venture Partners Advent Life Sciences GV (Google Ventures)OUP (Osage University Partners)Aisling Capital Vida Ventures Westlake Village BioPartners Lightspeed Venture Partners Menlo Ventures Versant Ventures Deerfield Management Company Third Rock Ventures Abingworth SV Health Investors Andera Partners Hatteras Venture Partners New Leaf Venture Partners Longwood Fund RTW Investments L.P.General Catalyst Bessemer Venture Partners Khosla Ventures Kleiner Perkins Trinity Ventures The Column Group Ysios Capital RiverVest Venture Partners Founders Fund CRV (Charles River Ventures)Tiger Global Management Meritech Capital Partners Venrock Pear VC General Atlantic Pitango EQT Life Sciences Dimension Capital Sofinnova Partners MPM BioImpact Domain Associates Pivotal Life Sciences Omega Funds Borealis Ventures Action Potential Venture Capital Ltd.CincyTech Signet Healthcare Partners Welsh, Carson, Anderson & Stowe Sequoia Capital DCVC (Data Collective)Polaris Partners Zetta Venture Partners Wildcat Venture Partners M12 (Microsoft's Venture Fund)BDC Venture Capital Forbion Flagship Pioneering Frazier Healthcare Partners Tencent Holdings 6 Dimensions Capital 1955 Capital Cofounders Capital +ND Capital DFJ Seroba Life Sciences JMI Equity Amplitude Venture Capital HBM Partners ACORN BIOVENTURES De Novo Ventures

Firms observed investing alongside OrbiMed, from public investor directories. Shared companies are the overlap with OrbiMed's recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Lumira Ventures

Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.

$1M – $10M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States

Website & social

orbimed.com

/orbimed-advisors @orbimed watch video

signal ↗crunchbase ↗

As published on the firm's website.

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

OrbiMed isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

ORBIMED ASIA PARTNERS III, L.P.Mar 2026 · 120 LPs$2.1BAUM

ORBIMED PRIVATE INVESTMENTS X, LPMar 2026 · 209 LPs$1.6BAUM

ORBIMED ASIA PARTNERS IV, L.P.Mar 2026 · 135 LPs$1.4BAUM

ORBIMED PRIVATE INVESTMENTS VII, LPMar 2026 · 145 LPs$1.1BAUM

OrbiMed Royalty & Credit Opportunities VMar 2026 · 237 LPsLPs: Kern County Employees' Retirement Association$1.1BAUM

ORBIMED ASIA PARTNERS V, LPMar 2026 · 95 LPs$947.9MAUM

ORBIMED ROYALTY & CREDIT OPPORTUNITIES V OFFSHORE, LPMar 2026 · 63 LPs$788.6MAUM

ORBIMED GENESIS MASTER FUND, L.P.Mar 2026 · 128 LPs$747MAUM

ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LPMar 2026 · 154 LPs$567.9MAUM

ORBIMED PARTNERS MASTER FUND LIMITEDMar 2026 · 126 LPs$535.1MAUM

ORBIMED ISRAEL PARTNERS II, L.P.Mar 2026 · 116 LPs$298.5MAUM

ORBIMED ROYALTY OPPORTUNITIES II, LPFeb 2026 · 272 LPs$168.1MAUM

+7 more funds · also operates 1 SPV

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

OrbiMed @orbimed

Congratulations to our portfolio company, Forte Biosciences, on its agreement to be acquired by @argenxglobal for $2.2 billion. This milestone follows impressive progress for Forte's lead program, FB102, including positive Phase 1b data in both vitiligo and celiac disease. With https://t.co/Tn0CXfP33r

Jul 27, 2026 · ♥ 6 · ⇄ 1

OrbiMed @orbimed

Congratulations to @Crinetics on its agreement to be acquired by Vertex Pharmaceuticals for $10B! OrbiMed has been proud to support Crinetics throughout its journey since 2018—from advancing a novel scientific platform to backing its IPO and beyond. This acquisition is a https://t.co/mRv6zuBn4p

Jul 7, 2026 · ♥ 2

OrbiMed @orbimed

We're proud to partner with The Oncology Institute on its strategic refinancing, providing a new $75 million term loan that strengthens the company's balance sheet, extends debt maturities, and enhances financial flexibility. We appreciate the opportunity to support The Oncology https://t.co/33MY8DliIQ

Jul 7, 2026 · ♥ 2